» Subscribe Today!
More of what you want to know.
The Daily News
X

Forgot your password?
Skip Navigation Links
Search results for 'GTx' | Search again
DeSoto Public Records:0
Shelby Public Records:5
Editorial:100
West Tennessee:0
Middle Tennessee:1
East Tennessee:0
Other:0

You must be a subscriber to see the full results of your search.

Please log in or subscribe below if you are not already a subscriber.

The Daily News subscribers get full access to more than 13 million names and addresses along with powerful search and download features. Get the business leads you need with powerful searches of public records and notices. Download listings into your spreadsheet or database.

Learn more about our services | Search again


Editorial Results (free)

1. GTx Scientific Officer Resigns -

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

2. GTx Scientific Officer Resigns -

James Dalton, the chief scientific officer and vice president of Memphis-based GTx Inc., will resign effective Aug. 31 to become dean of the University of Michigan College of Pharmacy.

3. Events -

Memphis Pink Palace Museum will host Dr. Jim Dalton of GTx Corp., presenting “Genetics, Race and Medicine,” Thursday, April 17, from 5 p.m. to 7 p.m. at the museum, 3050 Central Ave. Cost is free. Visit memphismuseums.org.

4. Events -

Kiwanis Club of Memphis will meet Wednesday, April 16, from noon to 1 p.m. at The University Club of Memphis, 1346 Central Ave. Don Johnson, bishop of the Episcopal Diocese of West Tennessee, will speak. Cost is $18 for nonmembers.

5. Steiner Resigns as CEO of GTx -

Dr. Mitchell Steiner has resigned effective Thursday from being CEO and vice chairman of GTx, the Memphis-based company he co-founded.

6. GTx Reports Net Loss, Improved Cash Position -

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

7. GTx Reports Net Loss, Improved Cash Position -

Memphis-based GTx reported a net loss of $7.8 million for the quarter ended Dec. 31 and an annual net loss of $42.1 million for 2013.

That compares to net losses of $10.7 million for the last quarter of 2012 and a net loss of $27.1 million for all of 2012.

8. RedRover Adds Trio of Employees -

RedRover Sales & Marketing has added three new employees to the roster.

They are creative director Carl Cottam, corporate trainer Lori Guy and marketing account executive Jennifer Seidman.

9. RedRover Adds Trio of Employees -

RedRover Sales & Marketing has added three new employees to the roster.

They are creative director Carl Cottam, corporate trainer Lori Guy and marketing account executive Jennifer Seidman.

10. Performance Ranges Widely at Local Companies -

Here’s a snapshot of the recent performance of some of Memphis’ publicly traded companies – businesses that cast a shadow far beyond the Memphis city limits in industries including finance, package delivery and bioscience.

11. GTx Layoffs Show Drug Market’s Volatility -

The layoffs at Memphis-based GTx Inc., announced Tuesday, Oct. 1, came with the resignation of the drug manufacturing company’s chief financial officer and pay cuts for GTx’s top three leaders.

12. GTx to Lay Off 60 Percent of Staff -

Memphis-based GTx is laying off 60 percent of its employees, according to a filing with the U.S. Securities and Exchange Commission.

The company expects to complete the downsizing, which will impact 53 “non-executive employees,” by Oct. 31, according to an 8K filing with the SEC. That will leave about 35 people.

13. GTx Treatment Fails to Meet Goals -

Shares of GTx Inc. plunged on Monday after the drugmaker said an experimental treatment with the potential to prevent and treat muscle wasting in cancer patients failed to meet its goals in two late-stage clinical trials.

14. GTx Says Muscle Drug Misses Late-Stage Study Goals -

Shares of GTx Inc. plunged Monday after the drug developer said its potential treatment for muscle wasting in lung cancer patients fell short of some main goals in late-stage clinical testing.

15. West Appointed Director of Wings Cancer Foundation -

Chris West has been appointed executive director of The Wings Cancer Foundation, a nonprofit organization that provides care to cancer patients and their families. He has been interim director for the past six months.

16. GTx Posts Quarterly, Yearly Net Loss -

Memphis-based biopharmaceutical company GTx Inc. has reported net loss of $10.7 million for the fourth quarter ended Dec. 31 compared to a similar $10.7 million net loss in Q4 2011.

17. GTx Drug Receives Fast-Track Status From FDA -

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

18. GTx Drug Receives Fast-Track Status From FDA -

An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration’s fast-track program.

19. GTx Drug Receives Fast-Track Status From FDA -

MEMPHIS (AP) – An experimental GTx Inc. treatment for muscle wasting in patients with a form of lung cancer will be reviewed under the Food and Drug Administration's fast-track program. Its shares climbed more than 12 percent in premarket trading.

20. GTx Rebounds in Third Quarter -

Memphis-based biopharmaceutical company GTx Inc. on Thursday, Nov. 8, reported net income of $7.4 million for the third quarter, fueled primarily from $18.8 million in net proceeds from the sale in early October of Fareston, a breast treatment medication.

21. Entrepreneurial Ecosystem -

Maybe you’re a startup founder who wants to rub shoulders with your peers, pitch investors in the hope of landing venture capital and talk to a lawyer about drawing up paperwork.

Maybe you’re a veteran researcher who’s got a side project that looks like it could turn into something big. Or maybe you’ve got little more than an idea on the back of a napkin.

22. GTx Narrows Q2 Loss -

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

23. GTx Narrows Q2 Loss -

GTx Inc. Wednesday, Aug. 8, reported a net loss of $10.4 million for the second quarter, compared to a net loss of $10.7 million for the same period in 2011.

24. UTHSC Breaks Ground On Research Building -

The University of Tennessee Health Science Center broke ground Friday, June 8, on its $49 million Translational Science Research Building, which will be built on the grassy lot at the northwest corner of Union Avenue and South Manassas Street.

25. Hill Joins Barge, Waggoner, Sumner & Cannon as CFO -

Certified Public Accountant Jason Hill has joined engineering and architectural firm Barge, Waggoner, Sumner & Cannon Inc. as chief financial officer.

26. UTHSC Prof. Receives $325K For Drug Discovery Instrument -

Dr. Wei Li, associate professor in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC), is the principal investigator of a $325,000 grant from the Office of the Director, a subsidiary of the National Institutes of Health.

27. GTx Reports $11.1 Million Q1 Net Income Loss -

Memphis-based biopharmaceutical company GTx Inc. on Tuesday, May 8, reported an $11.1 million net loss for the first quarter, compared to a net loss of $2.6 million for the same period in 2011.

28. Steiner, GTx Inc. Prepare For Next Step of Journey -

Dr. Mitchell Steiner recently returned from a trip to Eastern Europe, where he visited hospitals participating in international clinical trials for the drug enobosarm, which is being developed by his Memphis-based public biopharmaceutical company GTx Inc.

29. Many Questions Raised Before Going Public -

As Facebook prepares for its multibillion-dollar initial public offering (IPO) next month, it sheds light on how companies – including local ones – decide whether to go public or not.

Memphis-based pharmaceutical company GTx Inc. went public in 2004 and local paper producer Verso Paper Corp. held its IPO in 2008, but the overall number of publicly traded companies both locally and nationally has dropped over the past two decades.

30. Performance Of Memphis Public Cos. Varies Widely -

Memphis is home to several publicly traded companies that have made an indelible mark on industries ranging from transportation to finance and manufacturing.

Here’s a snapshot of how those companies are faring at the moment. (For a detailed look at AutoZone, see related story, "The Fast Lane.")

31. GTx Sends FDA Info on Prostate Drug -

GTx Inc. said Wednesday, April 4, that it is starting discussions with the U.S. Food and Drug Administration about resuming trials of its experimental prostate cancer drug Capesaris.

32. Ambitious Growth on Tap For Med Communications -

Pharmaceutical consulting firm Med Communications Inc. is expanding its presence in Memphis, with plans to soon move into a larger office space to accommodate anticipated growth over the next several years.

33. Panel: State Has ‘Robust’ Bioscience Community -

Members of the region’s scientific, medical, academic and business communities seeking more knowledge about innovative early-stage investment strategies in the biosciences packed the ballroom of The University Club, 1346 Central Avenue, on Thursday, Feb. 23, for a panel discussion hosted by Memphis Bioworks Business Association.

34. FDA Places Hold on GTx Study as Company Reports Earnings Drop -

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

35. FDA Places Hold on GTx Study as Company Reports Earnings Drop -

Memphis-based pharmaceutical company GTx Inc. on Tuesday, Feb. 21, announced that the U.S. Food and Drug Administration had placed a clinical hold on the company’s Phase II clinical studies for Capesaris.

36. GTx Shares Up Sharply After Citigroup Report -

Shares of GTx Inc. rose about 50 percent Monday, Jan. 30, after Citigroup predicted the Memphis-based pharmaceutical company was likely about a year away from reporting positive results from its Phase III clinical trials for Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

37. GTx Shares Rise 50 Pct. After Positive Citigroup Report -

Shares of GTx Inc. rose about 50 percent Monday, Jan. 30, after Citigroup predicted the Memphis-based pharmaceutical company was likely about a year away from reporting positive results from its Phase III clinical trials for Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

38. Biz Community Still Seeking Stable Ground -

Small business in 2011 was a mixed bag of serious market hurdles and fresh opportunities for innovation, depending on who you ask.

Many small businesses struggled to navigate a lackluster economy in which millions remained jobless and the outlook for consumer confidence and companies’ confidence in hiring and investing remained generally bleak.

39. Cross Creek Shopping Ctr. Sells for $12.7 Million -

3469 Riverdale Road, 3505 Riverdale Road and 3587 Riverdale Road
Memphis, TN 38115
Sale Amount: $12.7 million

40. Deal Closes on $2.6M Sale of Highland Row Property -

Worthington Hyde Partners, working under the name Highland Row Land Partners LLC, has bought the 13 acres of vacant land slated to become Highland Row from Poag & McEwen Lifestyle Centers – Memphis LLC for $2.6 million. The deal closed Thursday, Nov. 17.

41. GTx Posts $9.3M Q3 Loss -

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

42. GTx Posts $9.3M Q3 Loss -

Memphis-based GTx Inc. reported Friday, Nov. 4, a $9.3 million loss for the third quarter as the company ramped up research and development on two drugs in clinical development programs.

43. Plotting a Course -

State and federal officials are developing new programs and legislation to bolster small businesses.Many companies are facing a variety of hurdles in a lackluster economy in which millions remain jobless and the outlook for consumer confidence and companies’ confidence in hiring and investing remain bleak. But what shape those hurdles have taken depends on who you ask.

44. UTHSC Unveils New Pharmacy College -

For more than a century, the University of Tennessee Health Science Center College of Pharmacy has served as center of pharmacy education, practice and research in the Mid-South.

And on the eve of UTHSC’s September Centennial Gala, the College of Pharmacy – previously housed in six buildings on the sprawling, urban campus on Madison Avenue – is finally getting a home of its own.

45. GTx Reports Net Loss of $10.7M -

Memphis-based pharmaceutical company GTx Inc. reported Tuesday, Aug. 9, a net loss of $10.7 million in the second quarter compared with a net loss of $12.9 million for the same period in 2010.

46. GTx Reports Q2 Loss of $10.7M -

Memphis-based pharmaceutical company GTx Inc. reported Tuesday, Aug. 9, the company saw a net loss of $10.7 million in the second quarter, compared with a net loss of $12.9 million for the same period in 2010.

47. GTx Offers 10 Million Shares -

Memphis-based biotechnology company GTx Inc. on Thursday, June 23, announced it is pricing 10 million shares of stock offered to the public at $4.75 per share.

48. GTx Inc., FDA to Begin Trials on Cancer Drug -

GTx Inc., a Memphis-based pharmaceutical company, has announced an agreement with the U.S. Food and Drug Administration to begin Phase III clinical trials to evaluate Ostarine, a drug designed to prevent and treat muscle wasting in cancer patients.

49. KIPP Memphis Hosts Dress for Success Day -

On Friday from 10 a.m. to 11 a.m., Memphis middle school students from KIPP (Knowledge is Power Program) DIAMOND Academy, 230 Henry St., will host Dress for Success Day, where students dressed in business attire will ask community leaders questions concerning their fields of work.

50. GTx, Ipsen Terminate Drug Collaboration -

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

51. GTx, Ipsen Terminate Drug Collaboration -

Memphis biopharmaceutical startup GTx Inc. said Wednesday it and French-based pharmaceutical giant Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene.

52. GTx Reports Q4 Loss, but 2010 Profit -

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

53. GTx Reports Q4 Loss, But 2010 Profit -

Memphis-based biopharmaceutical company GTx Inc. Thursday reported a $7.5 million net loss in the fourth quarter, but posted a $15.3 million profit for the full-year, ended Dec. 31.

54. GTx Reports Q4, Full-Year Financial Results -

GTx, Inc. (Nasdaq: GTXI) today provided a company update and reported financial results for the fourth quarter and full year 2010.

55. GTx Therapy Shows Promise in Prostate Cancer Treatment -

Clinical trials of Capesaris, a drug developed by Memphis-based GTx Inc., have shown promise in the treatment of advanced prostate cancer. The findings were presented this past weekend at the Annual Meeting of the Society of Urologic Oncology in Bethesda, Md.

56. GTx Cuts Loss, Gets More Capital -

Memphis-based GTx Inc. completed its public offering of additional stock with help from another major investment by Joseph R. “Pitt” Hyde III.

57. GTx Cuts Loss, Gets More Capital -

Memphis-based GTx Inc. completed its public offering of additional stock with help from another major investment by Joseph R. “Pitt” Hyde III.

58. GTx Receives Government Grants -

GTx Inc. has been awarded $1.2 million in federal grants from the Qualifying Therapeutic Discovery Project Program.

The $1 billion program was established by the Patient Protection and Affordable Care Act, the health care reform law.

59. GTx, Needing Cash, Issues More Stock -

Memphis-based GTx Inc. will issue more stock in a bid to shore up its operating reserves.

The biopharmaceutical company needs more money to finance clinical trials and have working capital, according to a filing it made this week with the U.S. Securities and Exchange Commission.

60. UTHSC Signs on for Eli Lilly Initiative -

The University of Tennessee Health Science Center is participating in a research program initiated by Eli Lilly and Co. to get first dibs on potential drug therapies.

61. GTx Announces Positive News for Drug -

GTx has announced that tests of a drug it is developing show its “potential as a new hormonal treatment for advanced prostate cancer,” according to Mitchell Steiner, CEO of the Memphis-based biopharmaceutical company.

62. GTx’s Loss Widens on News of Abandoned Drug -

The write-off of investments related to the development of a drug that didn’t pan out caused GTx Inc. to have a bigger loss during the second quarter.

63. GTx’s Loss Widens on News of Abandoned Drug -

The write-off of investments related to the development of a drug that didn’t pan out caused GTx Inc. to have a bigger loss during the second quarter.

64. Study: Drug Helped Women Without Side Effects -

Ostarine, a drug that Memphis-based GTx Inc. is developing for cancer wasting, was noted to have improved body mass and leg strength in the first study conducted exclusively on postmenopausal women.

65. Hyde Increases Stake In GTx Stock -

Joseph R. “Pitt” Hyde III, the largest shareholder of Memphis-based biopharmaceutical company GTx Inc., continues to increase his stake in the company.

66. Study: GTx Drug Shows Promise -

A midstage Phase IIb study of the GTx Inc. drug Ostarine shows that the drug therapy helps cancer patients with fatigue and anorexia who are suffering from muscle wasting, the Memphis-based biopharmaceutical company said.

67. GTx CEO Upbeat Despite Drug Setback -

Dr. Mitch Steiner, the chief executive officer of GTx Inc., said the company is moving ahead with the other drug therapies it is developing after one intended to prevent prostate cancer did not show significant results in a clinical study.

68. GTx Faces Setback With Drug Trial -

GTx Inc. has reported a setback with one of the potential drug therapies in its pipeline, a treatment to prevent prostate cancer in men at high risk for the disease.

69. Powerful Possibilities -

Oct. 29 turned into a day for window staring when the news came.

The top executives of GTx Inc. looked at the bleak gray of an overcast sky from the seventh floor of the Toyota Center, their minds gone blank.

70. Daily News Recognized for State’s Best Website -

The Daily News Online and Senior Reporter Andy Meek took top honors in the annual Associated Press state awards over the weekend.

71. Memphis Daily News Scores TAPME Awards -

The Daily News Online was named the best website among Division 4 newspapers in the annual TAPME (Tennessee Associated Press Managing Editors) awards Saturday evening in Nashville.

And Daily News Senior Reporter Andy Meek won the Malcolm Law Investigative Reporting Award for his coverage of Consulting Services Group (CSG), a consultant to Shelby County government on its pension fund investments.

72. GTx Reports $44.3M Net Income -

GTx Inc. is pressing ahead with the development of a drug for muscle wasting in cancer patients after ending its partnership with Merck.

73. GTx CEO Addresses Ipsen Partnership -

The chief executive officer of GTx has learned a thing or two about partnerships as the Memphis-based biopharmaceutical company has struggled for profitability.

In the span of a week, GTx announced it was ending its two-and-a-half year partnership with Merck & Co. It then expanded its partnership with another pharmaceutical giant, Ipsen, of France.

74. GTx Affirms Partnership With Ipsen -

A week after ending its partnership with Merck & Co., Memphis-based GTx Inc. confirmed an expansion of its partnership with French pharmaceutical giant Ipsen.

75. GTx, Merck Part Ways -

Memphis-based GTx Inc. has ended its partnership with Merck & Co. to develop a drug to prevent wasting and muscle loss in cancer patients.

76. 2010 -

Is it over yet? That may be the most frequently asked question in the New Year. “It” is the worst national economic recession since the Great Depression.

Accurately reading the indicators will not be easy. Some will predict the recession is about to end, just as new indicators point to continuing economic agony for thousands of Memphians.

77. GTx Lays Off 28 Pct. of Work Force -

GTx on Friday laid off 28 percent of its work force, a reduction that is a direct result of the U.S. Food and Drug Administration’s decision on Oct. 30 to not grant approval of a drug the Memphis-based company is developing.

78. UPDATE: GTx Announces Lay-Offs -

GTx said today it laid off 28 percent of its work force, a reduction that is a direct result of the U.S. Food and Drug Administration’s decision on Oct. 30 to not grant approval of a drug the Memphis-based company is developing.

79. GTx Releases Earnings Report, Touts Other Drugs -

What a difference a week makes.

Seven days after explaining why the U.S. Food and Drug Administration did not approve its first drug product, Memphis-based GTx Inc. hosted a second conference call Monday when it reported earnings for the third quarter.

80. GTx Receives ‘Complete Surprise’ From Food and Drug Admin -

The stock of Memphis-based GTx Inc. plunged 45 percent Monday morning after the company explained why the U.S. Food and Drug Administration did not grant approval for its drug to prevent bone fractures in men with prostate cancer who are undergoing hormone deprivation treatment.

81. FDA Approval of GTx Drug Could Come Today -

The U.S. Food and Drug Administration is expected to announce today whether it will approve the use of a GTx Inc. drug to help prevent bone fractures in prostate cancer patients undergoing treatment with testosterone deprivation therapy.

82. GTx Progresses With Drug Therapy -

The independent Data Safety Monitoring Board has recommended that GTx continue as planned the Phase III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men considered at high risk for the disease.

83. GTx CEO Rings Bell To Open NASDAQ Trading -

Dr. Mitch Steiner, the chief executive officer of Memphis-based GTx Inc., rang the bell to start stock trading on the NASDAQ Thursday morning.

84. GTx Reports Smaller Net Loss in Q2 -

Memphis-based biopharmaceutical company GTx Inc. provided a timetable for the rollout of potential new therapies Monday when it released its second quarter earnings report.

The company, which is about to transition from the research and development phase to marketing new therapies, had a net loss of $11.3 million for the quarter compared to a net loss of $13.2 million for the same period a year ago. GTx, which has no debt, also said it has cash on hand of $68.9 million.

85. Baldwin Joins Visible School As Department Chair, Professor -

George Baldwin has been hired by Visible School as department chair and assistant professor of music business ministry and audio production.

86. State Venture Fund Established For High-Growth Startups -

Gov. Phil Bredesen last week signed into law legislation that will provide venture money for new companies with high growth potential, such as those involved in biotechnology and other innovations.

87. GTx Inc. Starts Trial for New Drug -

GTx Inc. has initiated a phase 1 multiple ascending dose clinical trial evaluating a new drug for first-line treatment of advanced prostate cancer. A phase 1 single ascending dose clinical trial in 96 subjects was completed in June.

88. Study: GTx Drug For Muscle Wasting Shows Promise -

A clinical trial of a GTx Inc. drug for muscle wasting in cancer patients shows benefits, according to a report the Memphis-based company released Thursday.

89. GTx Prepares for Market Launch -

GTx Inc. is exploring whether to hire its own sales force or partner with another entity as it prepares to transition from a company almost exclusively involved in research and development to one with its own products.

90. UTHSC Professor Dagogo-Jack Appointed A.C. Mullins Chair -

Samuel Dagogo-Jack has been appointed to the A.C. Mullins chair in Translational Research, an endowed professorship, at the University of Tennessee Health Sciences Center. Dagogo-Jack has also been named chief of the Division of Endocrinology for the Department of Medicine in the College of Medicine.

91. GTx Releases Bone Fracture Study -

Nearly one in four men with prostate cancer being treated with androgen deprivation therapy suffered bone fractures or had critical bone loss, Memphis-based GTx Inc. reported Monday.

92. GTx to Present Clinical Trial Data -

GTx Corp. reported Wednesday that it will present data from the clinical trial of a new drug Sunday during the 2009 Annual Meeting of the American Urological Association in Chicago.

93. Former GTx Employee Sues Over Stock Option -

While executives at Memphis-based GTx Inc. continue to exercise stock options in advance of the possible release of new drug therapies, a former employee of the pharmaceutical company is suing in federal court for her right to cash in any windfalls.

94. Merck to Buy Schering-Plough -

The company that Abe Plough founded in Memphis no longer will bear his name under terms of a $41.1 billion merger announced Monday between Merck & Co. Inc. and Schering-Plough Corp.

95. GTx: FDA Will Rule On Bone Drug By Oct. -

GTx Inc. reported Thursday that the U.S. Food and Drug Administration plans to make a ruling on the company’s bone drug toremifene by Oct. 30.

96. GTx Starts Trial For New Drug -

GTx Inc. reported Monday it has initiated Phase 1 clinical trial of GTx-758, another drug to treat men with advanced prostate cancer.

97. GTx’s Bone Fracture Drug Under FDA Review -

Biopharmaceutical company GTx Inc. said Wednesday the U.S. Food and Drug Administration is reviewing its application for the drug candidate toremifene.

98. GTx Plans to Hire 65 Salespeople, Posts Losses -

GTx will hire up to 65 pharmaceutical salespeople this year once the company hears back from the U.S. Food and Drug Administration about a regulatory review of toremifene for the prevention of bone fractures in men with prostate cancer who are on androgen deprivation therapy.

99. Schuler Buys Stake in GTx -

Jack Schuler, an investor who has held top leadership posts in the pharmaceutical and biotech industries, last week purchased 8.3 percent of the shares of GTx Inc. for himself, his foundation and his children.

100. UTHSC’s Miller Honored For Medicinal Chemistry Work -

Dr. Duane D. Miller has been inducted into the American Chemistry Society’s Medicinal Chemistry Hall of Fame.

Miller, a professor at the University of Tennessee Health Science Center and an executive with GTx, co-discovered and first described in medical literature a new class of drugs, selective androgen receptor modulators (SARMS), which have the potential to treat muscle wasting and other musculoskeletal conditions.